VOLUNTARY ANNOUNCEMENT - SYH2062 INJECTION (siRNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL

Hong Kong Exchanges and Clearing Limited and The Stock Excha nge of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoe ver for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this ann ouncement. CSPC PHARMACEUTICAL GROUP LIMITED (Incorporated in Hong Kong with limited liability) (Stock Code: 1093) ʮ ̡ VOLUNTARY ANNOUNCEMENT SYH2062 INJECTION (siRNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL The board of directors (the ‘‘Board ’’) of CSPC Pharmaceutical Group Limited (the ‘‘Company ’’, together with its subsidiaries, the ‘‘Group ’’) is pleased to announce that SYH2062 Injection (a double- stranded small interfering RNA (siRNA) drug) (the ‘‘Product ’’), a Class 1 new chemical drug independently developed by the Group, has obtained approva l granted by the National Medical Products Administration of the People ’s Republic of China to conduct clinical trials in China. The Product is a siRNA drug which delivers through N-acetylg alactosamine (GalNAc) conjugation. It can target and inhibit angiotensinogen (AGT) for the treatm ent of hypertension. The Product can achieve a more sustained gene silencing effect through sequ ence optimization and chemical modification strategy, with the potential to become a stabl e antihypertensive drug administered once every six months. Preclinical studies demonstrated that th e Product had a significantly longer duration of pharmacological activity than other siRNA products of th e same type. It is expected to have differential advantages of long-lasting efficacy, good sa fety profile and improved medication adherence, providing a promising clinical development val ue. By order of the Board CSPC Pharmaceutical Group Limited CAI Dongchen Chairman Hong Kong, 23 December 2024 As at the date of this announcement, the Board comprises Mr. C AI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chu nlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Steph en and Ms. LI Quan as independent non-executive directors.

The release as fetched from its publisher. irasia.com ↗